Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AGI-134 |
Synonyms | |
Therapy Description |
AGI-134 is a synthetic glycolipid consisting of an alpha-Gal trisaccharide and lipid tail, which potentially induces cytotoxicity and leads to tumor regression (PMID: 31889898). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AGI-134 | AGI 134|AGI134|aGal AGI-134|Alpha-Gal AGI-134 | AGI-134 is a synthetic glycolipid consisting of an alpha-Gal trisaccharide and lipid tail, which potentially induces cytotoxicity and leads to tumor regression (PMID: 31889898). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03593226 | Phase Ib/II | AGI-134 | Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour | Completed | USA | GBR | 1 |